Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.44 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19219769 | 0.91 | USP2 (0.49) | USP2MAPTESR2HSD17B10SCN9A | |
| SCHEMBL17545147 | 0.88 | ACLY (0.54) | USP2MAPTESR2HSD17B10SCN9A | |
| SCHEMBL17545288 | 0.83 | LMNA (0.50) | LMNAPKMKMT2AHPGDTRIM24 | |
| SCHEMBL17545074 | 0.80 | KMT2A (0.52) | LMNAPKMKMT2AHPGDTRIM24 | |
| SCHEMBL17545073 | 0.80 | CYP11B2 (0.52) | LMNAPKMKMT2AHPGDTRIM24 | |
| SCHEMBL29707960 | 0.79 | NOTUM (0.51) | LMNAPKMKMT2AHPGDTRIM24 | |
| SCHEMBL15882573 | 0.79 | NOTUM (0.51) | LMNAPKMKMT2AHPGDTRIM24 | |
| SCHEMBL19219768 | 0.79 | ACLY (0.44) | USP2MAPTESR2HSD17B10SCN9A | |
| SCHEMBL21469267 | 0.78 | CYP11B2 (0.43) | SCN3ALMNAPKMKMT2AHPGD | |
| SCHEMBL17545211 | 0.77 | TRIM24 (0.47) | LMNAPKMKMT2ATRIM24CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021469-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | LOYOLA UNIVERSITY OF CHICAGO (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190337931-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO | 2019-11-07 | — | — | US | disclosed |
| EP-3180312-B1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | UNIV LOYOLA CHICAGO (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10385040-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | LOYOLA UNIVERSITY OF CHICAGO (US) | 2019-08-20 | — | — | US | disclosed |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
| WO-2016025637-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385040-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | INMT, MGAM, NNMT | USP2 2795/4885MAPT 2069/4885ESR2 4156/4885 |
| US-20190337931-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | USP2 2795/4885MAPT 2069/4885ESR2 4156/4885 |
| US-11021469-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | INMT, MGAM, NNMT | USP2 2795/4885MAPT 2069/4885ESR2 4156/4885 |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | USP2 2795/4885MAPT 2069/4885ESR2 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.